Navigation Links
Court Grants Preliminary Approval to Class Action Settlement that Provides Benefits Of Approximately $20 Million to Healthcare Providers that Purchased a SS1 Before January 1, 2009
Date:3/4/2011

ble healthcare providers on the Transition List will be sent notice of the settlement.  The settlement applies to approximately 20,000 SS1 Devices owned by approximately 6,600 customers.   Based on the number of Eligible SS1 Devices and settlement options made available to each, C&T estimates that the settlement provides approximately $20 million of benefits to the class.  

The benefits that class members can elect to receive differs depending on whether they are members of Sub-Class A, Sub-Class B, or Sub-Class C:  Sub-ClassDescription

Settlement ConsiderationA

Class Members that (a) purchased or elect to purchase SYSTEM 1E™  ("SS1E") Device from STERIS on or before December 31, 2012, and (b) either (i) still have the Eligible SS1 Device(s) or (ii) returned the Eligible SS1 Device(s) to STERIS in the Rebate Program.  The SS1E is STERIS' next generation liquid chemical sterilant processing system.

Will receive SS1E Credits in the amount of $1,000.00 per Eligible SS1 Device, which can be applied towards the purchase of any SS1E Accessories, Parts Or Consumables; SS1E credits can be combined, and must be claimed by December 31, 2012.Class Members that (a) do not elect to purchase an SS1E Device and (b) either (i) still have the Eligible SS1 Device(s) or (ii) returned the Eligible SS1 Device(s) to STERIS in the Rebate Program.

Will, for each Eligible SS1 Device, have the option to receive either (a) $500 in STERIS Product Credits, or (b) $300.00 in cash.  STERIS Product Credits may be redeemed for any STERIS product(s) other than an SS1E Device, service, or service contracts.  STERIS Product Credits can be combined and must be claimed by December 31, 2012. C

Class Members that, for any reason other than because the Eligible SS1 Device was returned to STERIS in the Rebate Program, no longer have the Eligible SS1 Device.

Will be entitled to receive a $200.00 cash payment
'/>"/>

SOURCE Chimicles & Tikellis LLP
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. German High Court Rules in Favor of AmniSure® as New European Guidelines Published
2. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
3. Court of Appeals Overturns $1.8 Billion Patent Verdict for Centocor Ortho Biotech Inc.
4. Final Superior Court Ruling on Trade Secret Lawsuit Favors Volcano Corporation and Its Axsun Subsidiary
5. Watson Announces Favorable District Court Ruling in Generic Mucinex® Patent Suit
6. Massachusetts Court Rules in Favor of Volcano and Against St. Jude Medical Subsidiary in Trade Secrets Case
7. Sensipar® Patents Upheld By District Court
8. U.S. District Court Rules from Bench in Lillys Favor, Confirms Validity of Alimta Patent
9. Occlutech Wins Dutch Appeal Court Ruling Against AGA Medical
10. Mylan to Appeal Court Decision in Generic Paroxetine Hydrochloride CR Case
11. Statement of Ben Anderson, Esq., Regarding Denial of Wyeths En Banc Petition to Sixth Circuit Court of Appeals in Major Drug Regulation Pre-emption Case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 About ... an X-linked disease, which generally affects the male ... and weakness. The disease is caused due to ... the lack of production of dystrophin (a protein ... The lack of dystrophin weakens muscle function, causes ...
(Date:9/2/2015)... 2, 2015  Array BioPharma Inc. (Nasdaq: ... Officer, Ron Squarer , will present at ... The public is welcome to participate in the ... website.Event: Wells Fargo Securities Healthcare ConferencePresenter: Ron Squarer, ... , 10:20 a.m. Eastern Time Webcast: www.arraybiopharma.com ...
(Date:9/2/2015)... , Sept. 2, 2015 About Chronic ... a malignant condition characterized by increased production of lymphocytes. ... B-lymphocytes and then it can spread to other parts ... later stages because of the slow buildup of the ... malignancy spreads to the spleen, liver, and lymph nodes. ...
Breaking Medicine Technology:Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 3Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3
... Nov. 3, 2010 DURECT Corporation (Nasdaq: DRRX ... September 30, 2010. Total revenues were $8.1 million for the ... for the three months ended September 30, 2009; revenues in ... of certain excipients used in REMOXY® to King Pharmaceuticals in ...
... Biotechnology, Inc. (OTC Bulletin Board: CSBR ), a ... tumor specific data to enhance the value of oncology drugs, ... Qualifying Therapeutic Discovery Project ("QTDP"). The QTDP was enacted as ... 2010. About Champions Biotechnology, Inc. Champions Biotechnology, ...
Cached Medicine Technology:DURECT Corporation Announces Third Quarter 2010 Financial Results 2DURECT Corporation Announces Third Quarter 2010 Financial Results 3DURECT Corporation Announces Third Quarter 2010 Financial Results 4DURECT Corporation Announces Third Quarter 2010 Financial Results 5DURECT Corporation Announces Third Quarter 2010 Financial Results 6DURECT Corporation Announces Third Quarter 2010 Financial Results 7Champions Biotechnology Awarded $1.46 million in Grants 2
(Date:9/3/2015)... ... September 03, 2015 , ... Advice columnist, ... of her debut book, “Stop Wasting Your Time Blaming Others for Your Life.” ... Hartley’s guide to overcoming life’s obstacles by taking full responsibility for one’s life ...
(Date:9/3/2015)... ... September 03, 2015 , ... For the second year ... Inc. 5000 list of fastest-growing private companies in America. President and Editor-in-Chief ... nation's companies have demonstrated such remarkably consistent high growth, particularly in the difficult ...
(Date:9/3/2015)... ... 03, 2015 , ... According to an Oncology Nurse Advisor article ... patients with oropharyngeal cancer (oral cancer) to be successfully diagnosed and treated for relapses ... HPV infections, which have a high rate of success in treatment and elimination of ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... 31, 2015: DiabetesSisters is pleased to announce the additional of Carol Wysham, MD, ... by current board members Diana Karczmarczyk, Donna Rice, David Warren, Matt Stella, Tricia ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... responsibility concierges; simplifying responsibilities which can impact the delicate life balance between work ... situation might be.” - Jeffrey R. Leaptrott, CEO , A LifeMinder Plus® Emergency ...
Breaking Medicine News(10 mins):Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 2Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 3Health News:Inc. 5000 Includes Intellicure, Inc., Two Years in a Row 2Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 2Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 3Health News:Carol H. Wysham, MD, Joins DiabetesSisters Board of Directors 2Health News:LifeMinder Plus® Announces Emergency Care Document Set Giveaway for America 2Health News:LifeMinder Plus® Announces Emergency Care Document Set Giveaway for America 3
... , VIENNA, Va., Sept. 2 ... developer of vaccines for the prevention and treatment of infectious diseases ... K convertible notes (the "Notes"). The Notes, which had an ... and were convertible into common stock. , , ...
... 2 Shari Tetrick says the scooter she rented for her husband, ... fine at home, but on a large ship and shore excursions, I ... I wasn,t going to let anything ruin this cruise." , , ... her father. "The Explorer of the Seas is HUGE and dad wouldn,t ...
... , , ... /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, ... developing and marketing Levulan(R) Photodynamic Therapy (PDT) and other products focused ... and Chief Executive Officer, will present a corporate overview at the ...
... children, study found , WEDNESDAY, Sept. 2 (HealthDay News) -- ... but a new study concludes that weight-loss surgery can break ... surgery before becoming pregnant had children who were less likely ... before the weight-loss surgery. , The study findings show ...
... Sept. 2 "Everyone is looking for ways to protect ... about my personal encounter with the virus. About three months ... where he describes his discovery of the relationship between chronic ... started taking Gene-Eden, a broad range antiviral supplement, to reduce ...
... WASHINGTON, Sept. 2 Danaher Corporation (NYSE: ... agreement with MDS Inc. (TSX: MDS; NYSE: MDZ ... includes a 50% ownership position in Applied Biosystems/MDS Sciex joint ... ownership position in the former Molecular Devices Corporation, a bioresearch ...
Cached Medicine News:Health News:CEL-SCI Corporation Announces Elimination of $8.3 Million Convertible Notes 2Health News:Special Needs Equipment Rentals Save the Day for Travelers with Physical Disabilities 2Health News:Special Needs Equipment Rentals Save the Day for Travelers with Physical Disabilities 3Health News:DUSA Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference 2Health News:Weight-Loss Surgery Breaks Families' 'Obesity Cycle' 2Health News:How to Protect Against the Swine Flu Virus: 'My Personal Experience with Gene-Eden(TM), a Broad Range Antiviral Supplement' 2Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 2Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 3Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: